Xtandi 40mg (Enzalutamide Capsules)

This specialty medication is manufactured abroad and is not registered or commercially marketed for retail sale in India. Access in India may require specific regulatory approvals or personal import permits as prescribed by relevant authorities. Under Named Patient Supply, SDP can serve you. To know the best price/cost of medicines in India, Call at 9891296838 or Email query@southdelhipharma.com to discuss.

Brand Name- Xtandi
API- Enzalutamide
Packaging- 28 Capsules
Strength- 40 mg
Manufacturer Name- Astelas

South Delhi Pharma can facilitate the supply of “Xtandi (Enzalutamide)” to all locations in the world and in India after fulfilling the legal requirement (if applicable). Xtandi (Enzalutamide) is a prescription drug and should be used under proper medical guidance and advice. The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

Category Prostate Cancer

Category Prostate Cancer

Disclaimer: Trademark shown are property of their respective owners and South Delhi Pharma (SDP) India does not lay any claim on them.

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDP is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

Query Form

Description

Description

What Xtandi is?

Enzalutamide / Xtandi is a nonsteroidal antiandrogen drug, indicated for the treatment of:

Metastatic castration-resistant prostate cancer (mCRPC).
Non-Metastatic castration-resistant prostate cancer (nCRPC).
Metastatic castration sensitive prostate cancer (mCSPC).

What Enzalutamide is?

Enzalutamide, sold under the brand name Xtandi, is a nonsteroidal antiandrogen (NSAA) medication which is used in the treatment of prostate cancer. It is indicated for use in conjunction with castration in the treatment of metastatic castration-resistant prostate cancer (mCRPC), nonmetastatic castration-resistant prostate cancer, and metastatic castration-sensitive prostate cancer (mCSPC).